Pulse Biosciences achieves enrollment target in international pivotal study
Pulse Biosciences enrolled 164 patients in its pivotal NANOPULSE-AF study ahead of schedule, demonstrating strong investigator interest in its cardiac catheter system.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed